Olema Pharmaceuticals, Inc.

Olema is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing targeted therapies for breast cancer and other hormone-driven cancers. The company's lead investigational candidate is palazestrant, an oral small molecule acting as a complete estrogen receptor antagonist and selective estrogen receptor degrader. Olema is advancing palazestrant in late-stage clinical trials both as a single agent and alongside approved targeted medicines for patients with advanced or metastatic breast cancer. A second clinical-stage candidate, OP-3136, functions as a selective inhibitor of KAT6 for breast cancer and other solid tumors. Olema does not currently have approved products or commercial sales, serving patients through clinical trials.

The company operates without internal manufacturing facilities, relying entirely on third-party contract organizations for drug production and supply. Olema conducts clinical studies in collaboration with pharmaceutical partners such as Novartis and Pfizer across target populations primarily in the United States and Europe. The provided text does not state the company's specific headquarters location.

Summary of the business section of Olema Pharmaceuticals's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of January 31, 2026, we had 131 employees, all of whom were full time, consisting of clinical, research, operations, regulatory, and administrative personnel.”